Abstract：OBJECTIVE: To study the effects of astragaloside on the expression of insulin-like growth factor-1 (IGF-1) and associated proteins in mice with viral myocarditis. METHODS: Sixty-five 4-week-old BALB/C mice were randomly divided into 5 groups: normal control, astragaloside control, untreated myocarditis, low-dose and high-dose astragaloside-treated myocarditis. The BALB/C mice in the later three groups were intraperitoneally injected with CVB3. The low-dose and high-dose astragaloside-treated myocarditis groups were given astragaloside of 0.07 and 0.6 mg/kg?d, respectively by intragastric administration. Fifteen days later, the samples of blood and muscular tissues were obtained. The expression of IGF-1 in plasma was measured using ELISA. The levels of IGF-1 and associated proteins in muscular tissues were measured by immunohistochemistry. The expression of IGF-1 mRNA in muscular tissues was examined by RT-polymerase chain reaction (RT-PCR). RESULTS: The expression of IGF-1 and associated proteins increased significantly in mice infected with CVB3. High-dose astragaloside treatment reduced the expression of IGF-1 and associated proteins, but low-dose astragaloside did not. CONCLUSIONS: High-dose astragaloside may reduce the expression of IGF-1 and associated proteins in mice with acute viral myocarditis, possibly thus providing protective effects on muscular tissues.
HE Chun-Zhi,LI Shuang-Jie. Effects of astragaloside on IGF-1 and associated protein expression in mice with acute viral myocarditis[J]. CJCP, 2011, 13(9): 751-754.
［1］Esfandiarei M, Suarez A, Amaral A, Si X, Rahmani M, Dedhar S, et al. Novel role for integrin-links in modulation of coxsackievirus B3 replication and virus-induced cardiomyocyte injury［J］.Circ Res, 2006, 99(4): 354-361.
［6］Sadat S, Gehmert S, Song YH, Yen Y, Bai X, Gaiser S, et al. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-1 and VEGF［J］. Biochem Biophys Res Commun, 2007, 363（3）: 674-679.
［8］Herio T, Kamide K, Takiuchi S, Yoshii M, Miwa Y, Matayoshi T, et al. Association of insulin-like growth factor-1 receptor gene polymorphisms with left ventricular mass and geometry in essential hypertension［J］. J Human Hypertens, 2010, 24(5): 320-326.
［9］Bright GM, Mendoza JR, Rosenfeld RG. Recombinant human insulin-like growth factor-1 treatment: ready for primetime［J］. Endocrinol Metab Clin North Am, 2009, 38(3): 625-638.
［12］Yamaguchi H, Komamura K, Choraku M, Hirono A, Takamori N, Tamura K, et al. Impact of serum insulin-like growth factor-1 on early prognosis in acute myocardial infarction［J］. Intern Med, 2008, 47(9): 819-825.
